Company: DHR
Filing Date: 2025-03-26
Form Type: ARS
Source: 0000313616-25-000085
Chunk: 190

Company: DANAHER CORP /DE/
Filing Date: 2025-03-26
Form: ARS
Chunk 190
---
 Financial Information to Corresponding Financial Information Presented in Accordance with GAAP

Sales Growth (Decline) by Segment, Core Sales Growth (Decline) by Segment % Change Year Ended 12/31/24 vs. Comparable 2023 Period Biotechnology Life Sciences Diagnostics Total Company Total sales (decline) growth (GAAP) (6.0%) 2.5% 2.0% 0.0% Impact of: Acquisitions/divestitures Currency exchange rates 0.0% 1.5% (6.0%) 1.5% 0.0% 1.0% (2.0%) 0.5% Core sales (decline) growth (non-GAAP) (4.5%) (2.0%) 3.0% (1.5%)

Operating Cash Flow to Net Earnings Ratio (GAAP) Free Cash Flow to Net Earnings Ratio (non-GAAP) All amounts presented above reflect only continuing operations, unless otherwise indicated. 1 Items reflect continuing operations as reported in 2019, which include Veralto. Year Ended ($ in millions) 12/31/24 12/31/23 12/31/191 Operating cash flow from continuing operations from above (GAAP) $6,688 $6,490 $3,657 Net earnings from continuing operations (GAAP) 3,899 4,221 2,432 Operating cash flow from continuing operations to net earnings from continuing operations conversion ratio 1.72 1.54 1.50 Year Ended ($ in millions) 12/31/24 12/31/23 12/31/191 Free cash flow from continuing operations from above (non-GAAP) $5,309 $5,119 $3,034 Net earnings from continuing operations (GAAP) 3,899 4,221 2,432 Free cash flow from continuing operations to net earnings from continuing operations conversion ratio (non-GAAP) 1.36 1.21 1.25 Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations Year Ended ($ in millions) 12/31/24 12/31/23 12/31/191 Cash Flows from Continuing Operations: Total cash provided by operating activities from continuing operations (GAAP) $6,688 $6,490 $3,657 Total cash used in investing activities from continuing operations (GAAP) $(1,981) $(